How good is tirzepatide for weight loss — and what do the trial results actually show?

You've read a headline figure, here's where it actually comes from

You've probably seen the 20% number somewhere. It sounds remarkable, and the scepticism is reasonable. So it's worth tracing it back to its source. SURMOUNT-1 was a randomised, placebo-controlled phase-3 trial involving 2,539 adults with obesity or overweight and at least one weight-related condition, but without type 2 diabetes. Participants took tirzepatide once weekly for 72 weeks alongside a reduced-calorie diet and increased activity. Those on the 15 mg dose lost an average of around 20–21% of their body weight. The 10 mg group averaged roughly 19.5%. Even the lowest active dose produced meaningful reductions compared with placebo.

Then came SURMOUNT-5, published in the New England Journal of Medicine, which put tirzepatide directly against semaglutide 2.4 mg in 751 adults with obesity over 72 weeks. Tirzepatide produced greater average weight loss. That is now the strongest head-to-head evidence available for any two licensed weight-management injectables in the UK.

What this means in practice varies between individuals. Trial averages describe a population, not a prediction for any one person. Lifestyle engagement, starting weight, metabolic health and tolerability all affect outcomes. Still, the scale of the evidence (across thousands of adults in the SURMOUNT programme) is why NICE formally recommended tirzepatide in December 2024 under technology appraisal TA1026. That recommendation is not given lightly.

Why tirzepatide works differently from earlier weight-loss injections

Tirzepatide is sold in the UK as Mounjaro, a once-weekly injection made by Eli Lilly. Its mechanism is the reason it sits at a different tier of results from the medicines that came before it. Most GLP-1 medicines act on a single gut-hormone receptor. Tirzepatide activates two: the GLP-1 receptor and the GIP receptor. Both are involved in appetite regulation, blood-sugar response and gastric emptying. Stimulating both pathways simultaneously appears to produce a stronger cumulative effect on calorie intake and satiety than either pathway alone.

In practical terms: appetite falls significantly, meals feel filling sooner, and the stomach empties more slowly, so hunger returns later. The result is a sustained reduction in calorie intake that most people find easier to maintain than conventional dietary restriction alone, though the medicine works alongside lifestyle changes, not instead of them.

Treatment starts at 2.5 mg, a dose calibrated to let your system adjust gradually, with titration upward managed by the prescribing clinician over subsequent months. The pen lives in the fridge door between doses; it's a routine that most people fit around other weekly habits without difficulty. If you want to understand how the weight-loss process unfolds over time on tirzepatide, the clinical picture is covered in more detail on that page.

Who is likely to see meaningful results, and where the limits are

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews the whole picture (current medications, medical history, any contraindications) before any treatment is approved. BMI alone does not guarantee suitability.

The medicine is a prescription-only treatment, so the process starts with a clinical consultation. What tirzepatide is used for in the weight-management context covers the licensed indications in more depth, including the role of lifestyle support alongside treatment. For people who want to weigh up the financial side before starting, the Mounjaro cost page explains what private treatment typically involves.

Results genuinely vary. Some people lose well above the trial average; others less so. People who are weighing up their options sometimes find it helpful to read whether Mounjaro is a good fit for weight loss before deciding whether to go ahead with a consultation. If a patient has not lost at least 5% of their body weight after six months at the highest tolerated dose, continuing treatment is reconsidered. That built-in review is part of how responsible prescribing works, it is not a reason to avoid starting, but it is worth knowing in advance.

Side effects and what to watch for

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are all reported, particularly after starting or moving up to a higher dose. For most people these are mild to moderate and ease over a few days to a couple of weeks. Eating smaller portions and avoiding high-fat meals during dose increases can help.

Less common but more serious effects require prompt medical attention. Severe stomach pain that spreads to the back (with or without vomiting) should be assessed urgently, as acute pancreatitis is a known infrequent risk with GLP-1 medicines. The MHRA's Yellow Card scheme lets patients report any suspected side effects directly. Pregnancy, breastfeeding and trying to conceive are all situations in which tirzepatide is not recommended; it is also not licensed for under-18s. Anyone on oral contraceptives should know that a non-oral method of contraception is advised for the first four weeks of treatment and for four weeks after any dose increase, as pill absorption may be reduced during that window.

If you want to explore whether tirzepatide could be right for your situation, it can also be worth reading a broader assessment of whether tirzepatide is a good option before taking the next step. Starting a free consultation with our prescribers is the first step. A named GPhC-registered prescriber reads every consultation on the same day, there is no algorithm making that call.